+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07399002

Safety and Performance of the Ultimaster Nagomi Stent for Long Coronary Lesions Using a One-Stent Approach

Led by Fundación EPIC · Updated on 2026-09-11

1039

Participants Needed

10

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing the use of the Ultimaster Nagomi stent in treating coronary artery disease, focusing on its safety and performance in real-world settings. This post-market clinical follow-up study aims to reaffirm the devices effectiveness and safety claims without comparing it to other treatments. Participants treated with the Ultimaster Nagomi drug-eluting stent DES will be followed according to standard hospital practice. The study includes patients with long coronary lesions suitable for a one-stent approach, and all treated lesions are intended to receive this stent. No comparator group is involved as the study observes routine clinical use. During the study, participants undergo assessments including angina status using the Seattle Angina Questionnaire and quality of life via the EuroQol five-dimensional questionnaire at baseline and 12 months. Researchers will track device and procedure safety, performance in complex lesions, and clinical outcomes like target lesion failure, cardiovascular death, and myocardial infarction over one year. The total study duration extends until 2029, with ongoing data collection and monitoring.

CONDITIONS

Brief Title

LONG NAGOMI™ PMCF STUDY

Research Team

T

TAMARA GARCIA CAMARERO, MD, PhD

F

FUNDACION EPIC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here